1. Home
  2. CRWD vs VRTX Comparison

CRWD vs VRTX Comparison

Compare CRWD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CrowdStrike Holdings Inc.

CRWD

CrowdStrike Holdings Inc.

HOLD

Current Price

$422.16

Market Cap

107.5B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$431.19

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRWD
VRTX
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
107.5B
115.7B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
CRWD
VRTX
Price
$422.16
$431.19
Analyst Decision
Buy
Buy
Analyst Count
48
29
Target Price
$505.93
$539.08
AVG Volume (30 Days)
2.8M
1.3M
Earning Date
03-03-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
$4,812,005,000.00
$2,488,652,000.00
Revenue This Year
$25.23
$10.81
Revenue Next Year
$21.57
$10.41
P/E Ratio
N/A
$28.35
Revenue Growth
21.71
46.20
52 Week Low
$324.50
$362.50
52 Week High
$566.90
$510.77

Technical Indicators

Market Signals
Indicator
CRWD
VRTX
Relative Strength Index (RSI) 55.48 37.34
Support Level $410.57 $430.32
Resistance Level $441.75 $462.87
Average True Range (ATR) 15.75 10.78
MACD 1.05 -1.94
Stochastic Oscillator 74.18 14.50

Price Performance

Historical Comparison
CRWD
VRTX

About CRWD CrowdStrike Holdings Inc.

CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: